Identification of Biphenylcarboxylic Acid Derivatives as a Novel Class of Bone Resorption Inhibitors

Abstract

Butanediol biphenylcarboxylic acid derivatives represent a new class of antiresorptive drug that might be of therapeutic value in the prevention and treatment of diseases characterized by osteoclast activation such as osteoporosis, cancer-associated bone disease, and Paget's disease of bone.